Get the Stockscreener App
0.27
9.15%
-0.0272
After Hours:
.27
Renovaro Inc stock is traded at $0.27, with a volume of 1.57M.
It is down -9.15% in the last 24 hours and down -21.67% over the past month.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
See More
Previous Close:
$0.2972
Open:
$0.3
24h Volume:
1.57M
Relative Volume:
0.52
Market Cap:
$59.33M
Revenue:
-
Net Income/Loss:
$-41.23M
P/E Ratio:
-0.3857
EPS:
-0.7
Net Cash Flow:
$-11.54M
1W Performance:
-6.54%
1M Performance:
-21.67%
6M Performance:
-65.93%
1Y Performance:
-81.38%
1-Day Range:
$0.264
$0.3099
1-Week Range:
$0.264
$0.3164
52-Week Range:
$0.264
$2.10
Renovaro Inc Stock (RENB) Company Profile
Name
Renovaro Inc
Sector
Industry
Phone
45 39179840
Address
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Compare RENB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RENB
Renovaro Inc
|
0.27 | 59.33M | 0 | -41.23M | -11.54M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Renovaro Inc Stock (RENB) Latest News
Renovaro Inc (RENB Stock: A Sea of Opportunity - investchronicle.com
Ratios Uncovered: Breaking Down Renovaro Inc (RENB)’s Trailing Twelve Months Metrics - DWinneX
Renovaro Obtains a U.S. Patent for its AI-Powered Platform for Medication Discovery and Diagnostics - MSN
Smart Healthcare Is Taking Over. Here's Where the Money's Headed - Finansavisen
Renovaro Inc. (NASDAQ:RENB) Shares Bought by Nuveen Asset Management LLC - Defense World
POAIRenovaro Issues Shareholder Letter and Provides Corporate Update - Revista ADVFN
Renovaro Biosciences Subsidiary CEO Resigns Abruptly - TipRanks
Deutsche Bank AG Takes $107,000 Position in Renovaro Inc. (NASDAQ:RENB) - Defense World
Renovaro subsidiary secures patent for drug discovery AI By Investing.com - Investing.com South Africa
RENB stock touches 52-week low at $0.27 amid market challenges - Investing.com Australia
Renovaro's BioSymetrics Unit Gets Notice of Allowance for New Patent - MarketScreener
Renovaro (RENB) Secures Patent to Enhance AI in Drug Discovery | - GuruFocus
Renovaro Inc. Skyrockets on AI Patent Win: What’s Fueling the Frenzy? - RagingBull
Renovaro (RENB) Secures Patent to Enhance AI in Drug Discovery | RENB Stock News - GuruFocus
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Di - GuruFocus
Renovaro subsidiary secures patent for drug discovery AI - Investing.com
Renovaro secures U.S. patent for AI-driven drug discovery, diagnostics platform - TipRanks
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform | RENB Stock News - GuruFocus
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform - GlobeNewswire
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 41,296 Shares of Renovaro Inc. (NASDAQ:RENB) - Defense World
Renovaro Inc. (NASDAQ:RENB) Shares Acquired by Northern Trust Corp - Defense World
Contrasting Stoke Therapeutics (NASDAQ:STOK) & Renovaro (NASDAQ:RENB) - Defense World
What Analysts Think About Renovaro Inc (NASDAQ: RENB)’s Potential Raise - Stocksregister
Court Denies Renovaro Motion for an Expedited Trial in July - GlobeNewswire
Predictive Oncology says court denies Renovaro motion for expedited trial - TipRanks
Predictive Oncology to defend against Renovaro’s claims in court By Investing.com - Investing.com Canada
Predictive Oncology (POAI) Addresses Legal Dispute with Renovaro - GuruFocus
Predictive Oncology to defend against Renovaro’s claims in court - Investing.com Australia
Court Denies Renovaro Motion for an Expedited Trial in July | POAI Stock News - GuruFocus
Delaware Court Rejects Renovaro's Rush to Trial Against Predictive Oncology, Cites Critical Delays - Stock Titan
Court Denies Renovaro Motion for an Expedited Trial in July | P - GuruFocus
Renovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology Merger - MSN
Major Moves And Shakes In Health Care Sector - Finimize
AI Could Add $461 Billion to Global Healthcare--And These New Platforms Are Leading the Charge - Nasdaq
Predictive Oncology Stock Hits 1-Month Low Amid Renovaro Legal Clash, But Retail Leans Bullish By Stocktwits - Investing.com India
UPDATERenovaro Inc. Announces Expedited Trial for 2025 Lawsui - GuruFocus
Court Fast-Tracks Renovaro's Lawsuit to Force Merger After Predictive Oncology's $545K Securities Breach - Stock Titan
Renovaro Sues Predictive Oncology (POAI) Over Merger Agreement D - GuruFocus
Renovaro Gets Expedited Trial in Predictive Oncology Merger Dispute - marketscreener.com
Renovaro announces expedited trial on suit to enforce Predictive Oncology merger - TipRanks
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology - The Manila Times
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology | RENB Stock News - GuruFocus
Renovaro Inc. Secures Ruling to Expedite Trial Against Predictive Oncology Over Breach of Merger Agreement - Nasdaq
Renovaro Inc Stock (RENB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Renovaro Inc Stock (RENB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| William Anderson Wittekind | 10% Owner |
Jul 17 '24 |
Sale |
1.46 |
16,362 |
23,889 |
841,433 |
| William Anderson Wittekind | 10% Owner |
Jul 15 '24 |
Sale |
1.41 |
21,954 |
30,955 |
875,795 |
2.10%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):